LB-100

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) signed a sales agreement with WallachBeth Capital, LLC, allowing up to $1.7M in common stock sales. Proceeds will fund working capital and LB-100 development. The company also reported executive changes, a collaboration amendment, and a Nasdaq compliance extension.

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) entered an At-the-Market Sales Agreement with WallachBeth Capital, LLC on January 6, 2025, allowing the sale of up to $1,700,000 in common stock. Proceeds will fund working capital, corporate expenses, and development of LB-100, its lead clinical compound. The Agent receives a 3.5% commission per share sold. The offering is under a shelf registration effective May 2, 2024, and will cease upon reaching the maximum amount, termination, or expiration of the registration.

Lixte Biotechnology Holdings, Inc. saw a 13.6% decline in short interest to 117,900 shares by December 15th. The stock opened at $2.03, with a market cap of $4.57 million and a PE ratio of -1.17. The company focuses on cancer drug development, with LB-100 in phase 1b trials for metastatic colon cancer.

Eric Forman resigned as VP and COO of Lixte Biotechnology Holdings, Inc., effective Dec 31, 2024, citing personal reasons. His employment agreement will terminate the same day. The company filed the required report on Dec 27, 2024, signed by CEO Bastiaan van der Baan.

GlobalData evaluates drug development stages and approval likelihood using historical data. LB-100, targeting PP2A, is in development for various cancers. Lixte Biotechnology focuses on PP2A inhibitors, with LB-100 as a lead candidate showing anti-cancer activity with minimal toxicity.

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) amended its Development Collaboration Agreement with the Netherlands Cancer Institute and Oncode Institute, pausing study activities until a Phase 1b trial combining LB-100 with a WEE1 inhibitor begins. The amendment includes a reduced annual budget and allows translational data analysis. LIXT and LIXTW are Nasdaq-registered.

LIXTE Biotechnology Holdings amends its Development Collaboration Agreement with the Netherlands Cancer Institute and Oncode Institute, temporarily halting study activities until a Phase 1b clinical trial of LB-100 with a WEE1 inhibitor in metastatic colorectal cancer patients begins. The collaboration will resume once the first patient is dosed, continuing for one year with a revised annual budget of €100,000. Lixte also received a Nasdaq extension to meet its minimum stockholders’ equity requirement by February 18, 2025, aiming to raise up to $4 million through equity offerings. The company has revised its director compensation policy to equity-based remuneration.

Lixte Biotechnology Holdings, Inc. filed an Amendment No. 1 to Form S-1 Registration Statement with the SEC on November 1, 2024, for the offering of up to 1,895,734 Units, each consisting of one share of common stock or one pre-funded warrant to purchase one share of common stock and 1.25 common warrants to purchase one share of common stock, aiming to raise up to approximately $4,000,000. The offering is conducted on a reasonable best efforts basis, with WallachBeth Capital LLC as the exclusive placement agent. The company intends to use the net proceeds for working capital and general corporate purposes. The securities are offered at a fixed price, expected to be issued in a single closing, and the offering will end no later than November 30, 2024. The company faces risks related to development and regulatory approval of its product candidates, including potential clinical trial holds due to serious adverse events, and compliance with Nasdaq listing requirements.

Researchers use mitochondria transfer to boost T cell efficacy in cancer immunotherapy, turn mice transparent with food dye for real-time imaging, engineer Toxoplasma gondii to deliver proteins across the blood-brain barrier, activate oncogenic signaling to make cancer cells vulnerable to stress response inhibitors, and design 'antinuclear missile' antibodies to target cancer cell nuclei.